1-(4-fluorophenyl)-2-(4-hydroxytetrahydro-2H-pyran-4-yl)ethane-1,2-dione | 1435770-41-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(4-fluorophenyl)-2-(4-hydroxytetrahydro-2H-pyran-4-yl)ethane-1,2-dione
• 英文别名: 1-(4-Fluorophenyl)-2-(4-hydroxyoxan-4-yl)ethane-1,2-dione；1-(4-fluorophenyl)-2-(4-hydroxyoxan-4-yl)ethane-1,2-dione
• CAS: 1435770-41-4
• 化学式: C₁₃H₁₃FO₄
• 分子量: 252.242
• InChiKey: PYZVZVLJBSXZRD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  63.6
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  1-(4-fluorophenyl)-2-(4-hydroxytetrahydro-2H-pyran-4-yl)ethane-1,2-dione 在 dipotassium peroxodisulfate 、 ammonium acetate 作用下， 以 水 、 溶剂黄146 为溶剂， 反应 23.0h， 生成 US10865384, Example 3a
  参考文献：
  名称：

  Tri-substituted imidazole analogues of SB203580 as inducers for cardiomyogenesis of human embryonic stem cells

  摘要：

  The p38 alpha mitogen-activated protein kinase (MAPK) inhibitor SB203580 had been reported to enhance the cardiomyogenesis of human embryonic stem cells (hESCs). To investigate if tri-substituted imidazole analogues of SB203580 are equally effective inducers for cardiomyogenesis of hESCs, and if there is a correlation between p38 alpha MAPK inhibition and cardiomyogenesis, we designed and synthesized a series of novel tri-substituted imidazoles with a range of p38 alpha MAPK inhibitory activities. Our studies demonstrated that suitably designed analogues of SB203580 can also be inducers of cardiomyogenesis in hESCs and that cell growth is affected by changes in the imidazole structures. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.03.103
• 作为产物：
  描述：

  4-((4-fluorophenyl)ethynyl)tetrahydro-2H-pyran-4-ol 在 potassium permanganate 作用下， 以 1,4-二氧六环 、 水 为溶剂， 以50%的产率得到1-(4-fluorophenyl)-2-(4-hydroxytetrahydro-2H-pyran-4-yl)ethane-1,2-dione
  参考文献：
  名称：

  Tri-substituted imidazole analogues of SB203580 as inducers for cardiomyogenesis of human embryonic stem cells

  摘要：

  The p38 alpha mitogen-activated protein kinase (MAPK) inhibitor SB203580 had been reported to enhance the cardiomyogenesis of human embryonic stem cells (hESCs). To investigate if tri-substituted imidazole analogues of SB203580 are equally effective inducers for cardiomyogenesis of hESCs, and if there is a correlation between p38 alpha MAPK inhibition and cardiomyogenesis, we designed and synthesized a series of novel tri-substituted imidazoles with a range of p38 alpha MAPK inhibitory activities. Our studies demonstrated that suitably designed analogues of SB203580 can also be inducers of cardiomyogenesis in hESCs and that cell growth is affected by changes in the imidazole structures. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.03.103

文献信息

• 2,4,5-TRI-SUBSTITUTED AZOLE-BASED CASEIN KINASE 1 INHIBITORS AS INDUCERS FOR CARDIOMYOGENESIS
  申请人：AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH

  公开号：US20170166867A1

  公开（公告）日：2017-06-15

  This invention relates to a method for inducing or enhancing the differentiation of pluripotent stem cells into cardiomyocyte via casein kinase 1 inhibition said method comprising culturing the stem cells in the presence of a medium comprising a casein kinase 1 inhibitor of the formula (I) or (II) or a stereoisomer, tautomer, or a salt thereof wherein R 1 , R 2 and R 3 independently from another represent hydrogen, optionally substituted alkyl, alkenyl, alkynyl, heterocyclyl, heteroaryl or aryl; X represents NR 4 , O or S; and R 4 represents hydrogen, optionally substituted alkyl, alkenyl, alkynyl, heterocyclyl, heteroaryl or aryl. The method can be used in the late phase of stem cell differentiation and in the compounds of formula (I) or (II) in combination with other small molecules can lead to especially high differentiation of stem cells into cardiomyocytes. The invention further relates to novel compounds which can be used in the method of the invention and kits for stem cell differentiation.